Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) and Equillium Inc. (NASDAQ:EQ) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals Inc.	N/A	84.73	7.49M	-0.63	0.00
Equillium Inc.	N/A	0.00	13.25M	-0.71	0.00

Table 1 highlights Cyclacel Pharmaceuticals Inc. and Equillium Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Cyclacel Pharmaceuticals Inc. and Equillium Inc.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals Inc.	0.00%	-38.8%	-31.9%
Equillium Inc.	0.00%	0%	0%

Liquidity

The Current Ratio and Quick Ratio of Cyclacel Pharmaceuticals Inc. are 5.2 and 5.2 respectively. Its competitor Equillium Inc.’s Current Ratio is 1.9 and its Quick Ratio is 1.9. Cyclacel Pharmaceuticals Inc. can pay off short and long-term obligations better than Equillium Inc.

Institutional and Insider Ownership

Institutional investors owned 4.1% of Cyclacel Pharmaceuticals Inc. shares and 27.1% of Equillium Inc. shares. Insiders owned 18.62% of Cyclacel Pharmaceuticals Inc. shares. On the other hand, insiders owned about 21.3% of Equillium Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cyclacel Pharmaceuticals Inc.	3.95%	6.58%	-4.32%	-44.24%	-44.97%	39.17%
Equillium Inc.	13.92%	-14.33%	-51.67%	0%	0%	-7.72%

For the past year Cyclacel Pharmaceuticals Inc. had bullish trend while Equillium Inc. had bearish trend.

Summary

On 5 of the 7 factors Cyclacel Pharmaceuticals Inc. beats Equillium Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companyÂ’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the companyÂ’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.